Abstract
Tumor-associated antigens (TAAs) recognized by cytotoxic T lymphocytes (CTLs) have been identified[ 1 Rosenberg S.A Immunol. Today. 1997; 18: 175-181 Abstract Full Text PDF PubMed Scopus (379) Google Scholar , 2 Boon T Coulie P.G Van den Eynde B Immunol. Today. 1997; 18: 267-268 Abstract Full Text PDF PubMed Scopus (496) Google Scholar ], and vaccination protocols using synthetic peptides that correspond to TAAs have been initiated. However, these protocols have several drawbacks: (1) their feasibility only for selected human tumors and major histocompatibility complex (MHC) HLA alleles; and (2) the potential selection in vivo of antigen-loss tumor-cell variants. Ideally, the TAAs used should be as heterogeneous as possible.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call